Asia Pharma R&D Leaders Summit 2017
March. 21 ( Tuesday ) to March 22 ( Wednesday ), 2017
Sponsor
Website:
Established in Germany in 1912, M+W Group has a strong and celebrated history of more than 100 years of excellent client service. We thrive on being an engineering-led project delivery construction company; and we exist to unlock the potential of our clients by delivering high-tech, complex engineering projects. Our clients achieve their goals with our technical solutions, and are fully assured that their projects and assets are in reputable hands. Represented in over 30 countries, M+W Group maintains staffing levels of 6,000 dedicated employees. As a privately owned company, we seek to deeply understand the needs and drivers of our clients, and we choose to form trusted partner relationships. We act predictably, whilst constantly communicating and managing expectations, so that we can meet our commitments. We always add value in terms of quality, cost, technical excellence and innovation.
Founded in 2004, Sundia MediTech Company Ltd. is a leading China-based CRO providing a broad range of high-quality, cost effective drug discovery and development services. Capitalizing on its broad service offerings, experienced scientists and advanced research facilities and equipment, Sundia helps its customers discover and develop novel drug candidates efficiently. Sundia currently provides services to over 160 customers globally, including a vast majority of the top 20 pharmaceutical and biotechnology companies in the world, as well as fast-growing biotechnology and specialty pharmaceutical companies and renowned academic and research institutions. Sundia currently boasts an experienced and strong R&D tem, comprised of over 700 employees, of over 70% have post-graduate degrees and an average of 15 years of relevant industry experience. The Company conducts its laboratory and development activities in three primary facilities in China: a) Shanghai Zhangjiang Hi-Tech Park; b) Shijiazhuang; and c) Taicang.
CrownBio is a Cutting Edge Translational Technology Company Making Precision Medicine a Reality
CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, cardiovascular, and metabolic disease Drug Discovery.
Our premier Translational Platforms for cancer and metabolic disease help our clients accelerate their new drug development programs. CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products. We are a global company with facilities across the world in the United States, United Kingdom, China, and Taiwan.
We Help our Clients Accelerate Drug Discovery, Gain Insight and De-Risk Ushering Candidates into the Clinic
As a comprehensive solution provider, CrownBio helps reveal the best clinical possibilities with our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™, and HuSignature™ platforms enabling the rapid translation of a lead compound into a successful clinical candidate.
CrownBio's cutting-edge, proprietary, Translational Technology Platforms provide robust and scientifically sound end-to-end solutions for preclinical drug development.
The Premier Translational Platforms for Advanced Drug Discovery From large-scale in vitro and in vivo efficacy studies of drug candidates, to running surrogate trials in tandem with human clinical trials, CrownBio's well-characterized Translational Platforms deliver comprehensive and catered solutions for biopharmaceutical companies. By providing the data needed to inform and accelerate oncology and cardiovascular and metabolic disease (CVMD) therapeutic development, CrownBio helps our clients make smarter decisions about their drug candidates.
With more experience than anyone in the industry, CrownBio's global resources help customers answer the most challenging questions about human biology.
CrownBio's portfolio of cutting edge technologies includes the world's largest commercial collection of validated Patient-Derived Xenograft (PDX) models. At CrownBio we are seeking to recapitulate the diversity and complexity of human cancer biology in the laboratory.
Our Translational Technology Platforms are helping our clients make precision medicine a reality.
Website:
Lee’s Pharmaceutical Holdings Limited (“Lee’s”) is a research-based Hong Kong biopharmaceutical company with more than 20 years of operation in China’s pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, clinical, regulatory, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 15 products in the market place. Lee’s focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee’s development program is lauded with over 40 product candidates stemming from both internal R&D efforts and collaborations with US, European and Japanese companies; including promising compounds to treat liver cancer and pulmonary hypertension.
In 2010, Lee’s has been honored an outstanding achievement in ranking “No. 2 of (China) Best Small-Cap” in the Asia’s Best Companies Poll conducted by the leading regional financial magazine FinanceAsia showing the extensive recognition in the investment community of its seasoned management and effective corporate governance. Since 2011, Lee’s was awarded as one of the “Best Under a Billion” companies by Forbes Asia. The election of the final 200 with entrepreneurial characteristics is based on earning growth, sales growth and shareholders’ return on equity in the past 12 months and over three years. The mission of Lee’s is to become a successful specialty biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com/ .
Website:
CVie Therapeutics Limited (CVie) is a subsidiary of Lee’s and a biopharmaceutical company that focuses on discovering, developing and commercializing novel targeted therapies for the treatment of cardiovascular/renal diseases with unmet medical need in the Greater China region, Europe, US and other international markets. Our development programs focus on the treatment of specific subsets of patients with cardiovascular/renal disorders through personalized medicines that target specific disease causative mechanisms and achieve better efficacy and safety profiles. · CVie is led by a management team with global experience and expertise in the discovery, development and commercialization of therapies for cardiovascular/renal diseases. Currently, CVie has two assets in ongoing Phase IIb clinical trials: Rostafuroxin for the pharmacogenomics treatment of Primary Hypertension and Istaroxime for the intravenous treatment of Acute Heart Failure. A phase II trial on renal proteinuria (diabetes) with Rostafuroxin is planned. Finally, Istaroxime analogs are under preclinical investigation for the oral treatment of Chronic Heart failure (CHF). CVie is looking for partnership in the development of our assets in western countries.
Beijing East IP Ltd. was founded by Dr. GAO Lulin, the founding Commissioner of the State Intellectual Property Office (SIPO), and a group of experienced Chinese and international attorneys to provide top quality intellectual property services in China. Beijing East IP Ltd. is a registered patent prosecution firm before the State Intellectual Property Office (SIPO). Together with Beijing East IP Law Firm, a registered law firm before the Justice Department of the People’s Republic of China founded and presided by Dr. GAO, we offer a complete set of intellectual property services ranging from patent and trademark prosecution, litigation to other intellectual property rights protections and enforcements. We also represent and provide consultations to multinational and Fortune 500 corporations in handling intellectual property issues and litigations arising out of their China portfolios. Our professionals are enthusiasts who devote their career in intellectual property and technology law to provide leading intellectual property services in China. Most of them obtained M.S. and Ph.D. in engineering or science from leading universities in China, Japan, U.S. and Europe. Our attorney’s enthusiasm and qualifications allowed them to acquire both extensive legal experiences and diverse technical expertise through handling many landmark intellectual property cases in China. Our managing team and attorneys possess some of the most valuable resources in China to provide clients top quality intellectual property services.
Shanghai Beshining Law Office was founded in 2013 by main partner Xue Qi and his team from Shanghai Zhixin Patent Agent Ltd., and its headquarters is located in Shanghai.
As one of the few leading law offices authorized to engage in patent and trademark, we currently house more than one hundred personnel including lawyers, patent attorneys, and other legal and technical professionals with diverse background and expertise.
Our partners and their team have been providing nearly thousands of domestic and foreign enterprises with full intellectual property legal service and comprehensive domestic and foreign legal service of patent, trademark, copyright, integrated circuit layout design, anti-unfair competition and trade secret. The quantities of patent applications, trademark applications and lawsuits are all top rated nationwide. Especially, our team in Chemistry, Pharmaceuticals and Biology in which we have 16 lawyers and 38 patent attorneys is in the top tier of China., and our firm enjoys a patent grant rate of over 90% for invention in such areas. For two consecutive years (2015-2016), our team was awarded the title of Outstanding IP Service Team in China by China IP Magazine and China Daily IPR Channel.
HD Biosciences Co., Ltd. is a biology-focused preclinical drug discovery contract research organization (CRO) with operation facilities in Shanghai, China and La Jolla, California. The company offers comprehensive service platforms around target validation, plate-based pharmacology, hit identification and lead discovery, therapeutic antibody discovery, in vivo pharmacology, as well as other research and development services. The company currently collaborates with eight of the world’s ten largest pharmaceutical companies and has established strategic partnership in many key R&D areas with the impacts to portfolio development. The strong scientific expertise, high quality and consistent deliveries, which constantly meet or exceed client’s expectations, have earned the company a great reputation in the industry and helped the company to build its widely recognized leadership in preclinical contract research services.
ScinoPharm is a leading process R&D and active pharmaceutical ingredients (API) manufacturing service provider to the global pharmaceutical industry. With its FDA approved cGMP production facilities in Taiwan and China, ScinoPharm offers services ranging from custom synthesis of early phase clinical materials to commercial production. ScinoPharm serves over 300 customers worldwide, including most brand and all top-ten generic pharmaceutical companies. Specialized in high potency APIs, ScinoPharm has developed a broad product portfolio in the oncology category and has filed DMFs in as many countries as possible, at >743 DMF registrations worldwide, with 52 in the US. ScinoPharm has built extensive technical expertise in the fields of small molecules and peptides over the last 19 years. The company’s strict adherence to intellectual property protection and compliance with environmental, health and safety codes makes it a preferred API supplier for major pharmaceutical companies as well as new drug development companies in contract research and manufacturing services. Already the leader in providing oncology APIs to regulated markets worldwide, ScinoPharm has been expanding into the field of oncological injectable formulations, which will provide a vertically integrated, one-stop-shop service for our existing API customers. For more information, please visit the company’s web site at http://www.scinopharm.com
Asia Pharma R&D Leaders Summit 2017  |  Telephone: +86 21 6172 6970  |  E-mail: kevin.tan@deliver-consulting.com
© 2016 Asia Pharma R&D Leaders Summit 2017- All rights reserved